Established in 2019, BioCentriq is a full-service, New Jersey-based Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapy. The company focuses on all stages of process development and clinical manufacturing, providing essential services to support the release of both autologous and allogeneic drug products. With expertise in viral vector process development and manufacturing, BioCentriq is adept at working with various cell and vector types. The company boasts 35,000 square feet of facilities, which include four, soon to be five, ISO-7 certified GMP manufacturing suites, a fully equipped process development laboratory, quality control and analytical method development laboratories, and training facilities.

Services include:
- Protein and Peptide
- Cell and Gene Therapy
- Viral Vector Development and Manufacturing

In summary, BioCentriq is committed to advancing the field of biopharmaceuticals through its comprehensive services and expertise. For more information, please visit biocentriq.com.